AFJKR
AFJKR
Aimei Health Technology Co., LtdIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $61.98K ▼ | $45.44K ▼ | 0% | $0.01 ▼ | $-61.98K ▲ |
| Q4-2025 | $0 | $250.59K ▲ | $98.12K ▼ | 0% | $0.02 ▼ | $-250.59K ▼ |
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▲ |
| Q1-2025 | $0 | $413.41K | $184.66K | 0% | $0.02 | $-413.41K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $18.52K ▲ | $12.29M ▲ | $4.21M ▲ | $8.09M ▲ |
| Q4-2025 | $2.93K ▼ | $12.1M ▼ | $4.06M ▲ | $8.04M ▼ |
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K | $43.6M | $2.38M | $41.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $45.44K ▼ | $-74.61K ▼ | $-68.66K ▼ | $158.86K ▲ | $15.59K ▲ | $-74.61K ▼ |
| Q4-2025 | $98.12K ▼ | $-43.23K ▲ | $33.69M ▲ | $-33.65M ▼ | $-50 ▼ | $-43.23K ▲ |
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K | $-224.01K | $30.79M | $-30.58M | $-20.86K | $-224.01K |
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
The main positives are strategic rather than purely financial. AFJKR has no interest‑bearing debt and a simple corporate structure, making it a clean vehicle for a merger. Through the proposed combination with United Hydrogen, it provides access to an integrated hydrogen platform with operating plants, refueling stations, and a portfolio of patents and innovative projects. United Hydrogen’s end‑to‑end solutions and city‑level operating model give it a differentiated position within the hydrogen ecosystem, with potential to benefit from global decarbonization trends.
On a stand‑alone basis, AFJKR’s financials are weak: no revenue, negative operating income, negative operating and free cash flow, severe liquidity constraints, and deeply negative equity. Sustainability depends on external funding and the successful completion of the merger. At the business level, the hydrogen sector is capital‑intensive, policy‑driven, and highly competitive, with uncertain long‑term economics. Regulatory approvals, integration challenges, technology risk, and the need for continuous investment all represent significant uncertainties for the future combined entity.
The outlook for AFJKR is highly contingent and binary: in its current form, it is a financially stressed shell with limited standalone prospects; if the merger with United Hydrogen closes and is well executed, it becomes a listed platform for an integrated hydrogen energy business with meaningful growth potential but also considerable risk. The near‑term focus will likely be on securing approvals, closing the transaction, and recapitalizing the balance sheet, while the medium‑term picture will hinge on whether United Hydrogen can convert its innovative projects and infrastructure into stable revenue, positive cash flow, and a durable competitive position in the global hydrogen market.
About Aimei Health Technology Co., Ltd
https://www.aimeihealth.comAimei Health Technology Co., Ltd presently has no significant ongoing business activities. Its main goal is to complete a strategic consolidation, such as a merger, stock swap, asset purchase, equity acquisition, financial restructuring, or another similar business combination, involving one or more companies or organizations.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $61.98K ▼ | $45.44K ▼ | 0% | $0.01 ▼ | $-61.98K ▲ |
| Q4-2025 | $0 | $250.59K ▲ | $98.12K ▼ | 0% | $0.02 ▼ | $-250.59K ▼ |
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▲ |
| Q1-2025 | $0 | $413.41K | $184.66K | 0% | $0.02 | $-413.41K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $18.52K ▲ | $12.29M ▲ | $4.21M ▲ | $8.09M ▲ |
| Q4-2025 | $2.93K ▼ | $12.1M ▼ | $4.06M ▲ | $8.04M ▼ |
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K | $43.6M | $2.38M | $41.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $45.44K ▼ | $-74.61K ▼ | $-68.66K ▼ | $158.86K ▲ | $15.59K ▲ | $-74.61K ▼ |
| Q4-2025 | $98.12K ▼ | $-43.23K ▲ | $33.69M ▲ | $-33.65M ▼ | $-50 ▼ | $-43.23K ▲ |
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K | $-224.01K | $30.79M | $-30.58M | $-20.86K | $-224.01K |
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
The main positives are strategic rather than purely financial. AFJKR has no interest‑bearing debt and a simple corporate structure, making it a clean vehicle for a merger. Through the proposed combination with United Hydrogen, it provides access to an integrated hydrogen platform with operating plants, refueling stations, and a portfolio of patents and innovative projects. United Hydrogen’s end‑to‑end solutions and city‑level operating model give it a differentiated position within the hydrogen ecosystem, with potential to benefit from global decarbonization trends.
On a stand‑alone basis, AFJKR’s financials are weak: no revenue, negative operating income, negative operating and free cash flow, severe liquidity constraints, and deeply negative equity. Sustainability depends on external funding and the successful completion of the merger. At the business level, the hydrogen sector is capital‑intensive, policy‑driven, and highly competitive, with uncertain long‑term economics. Regulatory approvals, integration challenges, technology risk, and the need for continuous investment all represent significant uncertainties for the future combined entity.
The outlook for AFJKR is highly contingent and binary: in its current form, it is a financially stressed shell with limited standalone prospects; if the merger with United Hydrogen closes and is well executed, it becomes a listed platform for an integrated hydrogen energy business with meaningful growth potential but also considerable risk. The near‑term focus will likely be on securing approvals, closing the transaction, and recapitalizing the balance sheet, while the medium‑term picture will hinge on whether United Hydrogen can convert its innovative projects and infrastructure into stable revenue, positive cash flow, and a durable competitive position in the global hydrogen market.

CEO
Junheng Xie
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 2
Ratings Snapshot
Rating : C+

